Table 1.
Clinical characteristics of the study patients on admission.
| Characteristics | All patients (n = 37) | Duration from onset to release from quarantine | ||
|---|---|---|---|---|
| ≤20-day (n = 19) | >20-day (n = 18) | P-value | ||
| Age (yrs.) | 44.3 ± 1.67 | 39.1 ± 1.79 | 49.9 ± 1.38 | 0.047 |
| Gender | ||||
| Male (%) | 17/37 (45.9) | 9/19 (47.4) | 8/18 (44.4) | 0.121 |
| Female (%) | 20/37 (54.1) | 10/19 (52.6) | 10/18 (55.6) | |
| Duration from onset to hospitalization (d) | 3 (5.5) | 2 (4) | 6 (5.25) | 0.016 |
| PSI | 45 (105) | 51 (53.5) | 44.5 (55.75) | 0.932 |
| I (%) | 17/37 (45.9) | 8/19 (42.1) | 9/18 (50.0) | |
| II ≤ 70 (%) | 16/37 (43.2) | 10/19 (52.6) | 6/18 (33.3) | |
| III 71–90 (%) | 3/37 (8.1) | 1/19 (5.3) | 2/18 (11.1) | |
| IV 91–130 (%) | 1/37 (2.7) | 0/19 (0) | 1/18 (5.6) | |
| V >130 (%) | 0/37 (0) | 0/19 (0) | 0/18 (0) | |
| Underlying disease | ||||
| Any (%) | 8/37 (21.6) | 4/19 (21.1) | 4/18 (22.2) | 1 |
| Hypertension (%) | 3/37 (8.1) | 1/19 (5.3) | 2/18 (11.1) | 0.604 |
| Coronary heart disease (%) | 3/37 (8.1) | 1/19 (5.3) | 2/18 (11.1) | 0.604 |
| Diabetes (%) | 2/37 (5.4) | 1/19 (5.3) | 1/18 (5.6) | 1 |
| Pulmonary Interstitial fibrosis (%) | 1/37 (2.7) | 0/19 (0) | 1/18 (5.6) | 0.486 |
| Cirrhosis, liver cancer (%) | 1/37 (2.7) | 0/19 (0) | 1/18 (5.6) | 0.486 |
| Epidemiological history | ||||
| Contact with wild (%) | 0/37 (0) | – | – | |
| Wuhan sojourn (%) | 6/37 (16.2) | 3/19 (15.8) | 3/18 (16.7) | 1 |
| Contact with a diagnosed patient or workplace (%) | 29/37 (78.4) | 15/19 (78.9) | 14/18 (77.7) | 1 |
| Not clear (%) | 2/37 (5.4) | 1/19 (5.3) | 1/18 (5.6) | 1 |
| Symptoms | ||||
| Asymptomatic (%) | 7/37 (18.9) | 7/19 (36.8) | 0/18 (0) | 0.008 |
| Fever (%) | 23/37(62.2) | 8/19 (42.1) | 15/18 (83.3) | 1 |
| ≤38.0°C (%) | 20 (87.0) | 7 (87.5) | 13 (86.7) | 1 |
| >38.0°C (%) | 3 (13.0) | 1 (12.5) | 2 (13.3) | |
| Chills (%) | 1/37 (2.7) | 0/19 (0) | 1/18 (5.6) | 0.486 |
| Fatigue (%) | 9/37 (24.3) | 1/19 (5.3) | 8/18 (44.4) | 0.008 |
| Headache (%) | 3/37 (8.1) | 0/19 (0) | 3/18 (16.7) | 0.105 |
| Nasal congestion (%) | 3/37 (8.1) | 2/19 (10.5) | 1/18 (5.6) | 1 |
| Sore throat (%) | 8/37 (21.6) | 0/19 (0) | 8/18 (44.4) | 0.001 |
| Cough (%) | 25/37(67.6) | 11/19 (57.9) | 14/18 (77.8) | 0.295 |
| Hemoptysis (%) | 1/37 (2.7) | 0/19 (0) | 1/18 (5.6) | 0.486 |
| Shortness of breath (%) | 12/37(32.4) | 3/19 (15.8) | 9/18 (50.0) | 0.035 |
| Vomiting or diarrhea (%) | 8/37 (21.6) | 5/19 (26.3) | 3/18 (16.7) | 0.693 |
| Pain in a muscle or joint (%) | 2/37 (5.4) | 1/19 (5.3) | 1/18 (5.6) | 1 |
| Laboratory findings | ||||
| WBC <4.0 × 109/L (%) | 10/37 (27.0) | 4/19 (21.1) | 6/18 (33.3) | 1 |
| L <1.1 × 109/L (%) | 23/37 (62.2) | 12/19 (63.2) | 11/18 (61.1) | 0.366 |
| L ≤ 0.6 × 109/L (%) | 10/23 (43.5) | 6/12 (50.0) | 4/11 (36.4) | 0.68 |
| SAA >10 mg/L (%) | 21/37 (56.8) | 10/19 (52.6) | 11/18 (61.1) | 0.743 |
| CRP >5 mg/L (%) | 19/37 (51.4) | 7/19 (36.8) | 12/18 (66.7) | 0.103 |
| PCT >0.5 ng/ml (%) | 1/37 (2.7) | 0/19 (0) | 1/18 (5.6) | 0.486 |
| LDH >250 U/L (%) | 6/37 (16.2) | 1/19 (5.3) | 5/18 (27.8) | 0.09 |
| Alb <40 g/L (%) | 24/37 (64.9) | 9/19 (47.4) | 15/18 (83.3) | 0.038 |
| AST >40 U/L (%) | 4/37 (10.8) | 3/19 (15.8) | 1/18 (5.6) | 0.604 |
| ALT >40 U/L (%) | 2/37 (5.4) | 1/19 (5.3) | 1/18 (5.6) | 1 |
| TBL >17.1 mmol/L (%) | 13/37(35.1) | 5/19 (26.3) | 8/18 (44.4) | 0.313 |
| D-dimer >0.5 mg/L (%) | 7/37 (18.9) | 4/19 (21.1) | 3/18 (16.7) | 1 |
| Fib >4 g/L (%) | 9/37 (24.3) | 4/19 (21.1) | 5/18 (27.8) | 0.714 |
| ESR ≥20 mm/h (%) | 24/37 (64.9) | 10/19 (52.6) | 14/18 (77.8) | 0.17 |
| Chest CT scan finding | ||||
| Pneumonia (%) | 32/37 (86.5) | 16/19 (84.2) | 16/18 (88.9) | 1 |
| Bilateral infiltration (%) | 22 (68.8) | 9 (56.2) | 13 (81.2) | 0.252 |
| Unilateral infiltration (%) | 10 (31.2) | 7 (43.8) | 3 (18.8) | |
PSI, pneumonia severity index; WBC, white blood cells; L, lymphocytes; SAA, serum amyloid A; CRP, C-reactive protein; PCT, procalcitonin; LDH, lactate dehydrogenase; Alb, albumin; AST, aspartate aminotransferase; ALT, alanine aminotransferase; TBL, total bilirubin; Fib, fibrinogen; ESR, erythrocyte sedimentation rate.